Using B cell depletion to stop autoimmune reactions in cancer treatment
B cell depletion to prevent autoimmunity
This study is looking at how a type of immune cell called B cells might cause unwanted side effects during cancer treatments that boost the immune system, especially in people who already have autoimmune conditions, so that doctors can better identify those at risk and find ways to prevent these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10665681 on NIH RePORTER |
What this research studies
This research investigates how B cells, a type of immune cell, contribute to immune-related adverse events (IRAEs) during cancer treatments that use immune checkpoint blockade. The study aims to understand the cellular and genomic changes in B cells that may lead to these adverse events, particularly in patients with preexisting autoimmune conditions. By analyzing the behavior of B cells in response to cancer therapies, the researchers hope to identify patients at risk for IRAEs and develop strategies to prevent these complications. The approach combines insights from cancer immunology and autoimmunity to create a comprehensive understanding of B cell function in these contexts.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients undergoing immune checkpoint blockade therapy who have a history of autoimmune disorders or are at risk for IRAEs.
Not a fit: Patients who are not receiving immune checkpoint blockade therapy or do not have autoimmune conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment protocols that minimize harmful immune reactions in patients.
How similar studies have performed: Previous studies have shown promising results in understanding the role of immune cells in cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Dhodapkar, Kavita Madhav — Emory University
- Study coordinator: Dhodapkar, Kavita Madhav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.